Australian-Singaporean regenerative medicine company Osteopore Limited (ASX: OSX; Osteopore or the Company) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the signing of a collaboration agreement between its subsidiary Osteopore International Pte Ltd and RxCell Inc (RxCell).
Highlights
- Osteopore signs collaboration agreement with US-based induced pluripotent stem cells (iPSC) company RxCell Inc (RxCell).
- RxCell is a leading-edge iPSC company based in Utah, USA.
- RxCell President and CEO Xianmin Zeng is a renowned stem cell biologist and neurobiologist with expertise in the development of PSC-based therapy and drug discovery.
- The agreement expands Osteopore into the scaffold-based cell therapy market, which is projected to surpass USD 4.39b by 2034.
RxCell is a leading-edge biotechnology company dedicated to advancing the frontiers of therapeutic applications through induced pluripotent stem cells (iPSC).
Combining the structural precision of scaffolds with the transformative power of cell therapy, this cutting-edge synergy pushes the boundaries of regenerative medicine, enabling
Osteopore to pioneer life-changing solutions that speed up recovery and unlock the body’s potential to regenerate, paving the way for improved patient outcomes.
RxCell Inc., (RxCell) RxCell Inc. is a leading biotechnology company focused on developing innovative cell therapies to treat degenerative diseases.
iPSC pioneer, RxCell President and CEO, Dr Xianmin Zeng focuses her research on neural development using iPSC to model neurodegenerative diseases. Dr Zeng was highlighted by the California Institute for Regenerative Medicine (CIRM) for her research into stem cells during her tenure as Professor at the Buck Institute for Research on Aging.
In 2012, the prominence of iPSCs grew significantly after Kyoto University Professor Shinya Yamanaka won the Nobel Prize.
Professor Yamanaka demonstrated that mature cells could be reprogrammed to become pluripotent, meaning they could transform into any cell type in the body, unlocking significant potential for targeted solutions. Since 2012, the development of iPSCs has progressed exponentially with a range of clinical studies commencing globally.
Under the scope of the 18-month agreement, Osteopore and RxCell will set up a Technology Advisory Committee (TAC) comprising one nominee from each party to assess co-development and resource utilisation opportunities.
Subsequently, Osteopore and RxCell may seek third-party funding to support growth and development opportunities in scaffold-based cell therapy.
Key highlights of the collaboration agreement:
- Capabilities and expertise: The collaboration will leverage Osteopore’s proprietary scaffold-based technology and RxCell’s cell-based therapeutic capabilities.
- Joint development: The parties will work together to co-design scaffold-based cellular products.
- Clinical testing: The collaboration will pave the way for pre-clinical studies to validate and progress the development of scaffold-based cellular products.
- Commercialisation strategy: Leveraging their networks and resources, the parties will collaborate on the commercialisation runway for scaffold-based cellular products.
Commenting on Osteopore’s ground-breaking move into scaffold-based cell therapy, Executive Chairman Mark Leong, said:
“We are excited and actively exploring cutting-edge cellular therapies for tissue regeneration, each unlocking new possibilities for breakthrough healing.
Combining our proven scaffold-based technology with cellular therapy is a game-changer—this powerful synergy will accelerate healing and drive full tissue regeneration. It’s the future where the body doesn’t just repair, it regenerates,” said Mr Leong.
Commenting on the synergies created by the RxCell collaboration, Osteopore CEO Dr Yujing Lim said:
“Leveraging Osteopore’s proven 3D-printed scaffold technology, our collaboration with RxCell signals our expansion into scaffold-base cell therapy. We are now looking towards the next stage of our synergy with cellular healing, where structure meets life.
“RxCell’s leadership in iPSC therapy, combined with our scaffold technology, unlocks powerful synergies that have the potential to not only improve patient outcomes but change the game for regenerative medicine,” said Dr Lim
Commenting on the collaboration’s potential to transform regenerative medicine, RxCell President & CEO Dr Xianmin Zeng, said:
“This collaboration is a key milestone for RxCell. Osteopore’s proven track record in clinical development and commercialisation complements our capabilities in stem cell therapy.
“Together, we have the potential to advance the field of regenerative medicine and bring new, transformative therapies to patients worldwide,” said Dr Zeng.